Abstract: The invention provides a method for improving the emotional development of an infant by performing controlled exposure of the infant aged less than six months old to human fear pheromone, preferably with visual fear stimuli, so that the natural synaptic connections in the brain associated with normal fear mechanisms are stimulated and exercised. This can reduce the occurrence of mental illness later in life, in particular reduce the occurrence of schizophrenia. Advantageously the exposure to fear pheromone and visual fear stimuli is terminated and followed by comforting stimuli such as feeding, physical contact, or comforting or happy visual or audible stimuli such as laughter.

Abstract: Thienopyrimidines of formula (Ia) or (Ib): wherein R1-R3 have any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase, in particular the p110 delta subtype, such as immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

Abstract: Thienopyrimidines of formula (Ia) or (Ib): wherein R1-R3 have any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase, in particular the p110 delta subtype, such as immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

Abstract: Thienopyrimidines of formula (Ia) or (Ib): wherein R1-R3 have any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase, in particular the p110 delta subtype, such as immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

Abstract: The invention provides a pyrimidine compound of formula (I): wherein R1 and R2 have any of the values defined herein; or a pharmaceutically acceptable salt thereof. The compounds are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

Abstract: The invention provides a pyrimidine compound of formula (I): wherein R1 and R2 have any of the values defined herein; or a pharmaceutically acceptable salt thereof. These compounds are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

Abstract: The invention provides a pyrimidine compound of formula (I): wherein R1, R2, and Y have any of the values defined herein; or a pharmaceutically acceptable salt thereof. The compounds are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

Abstract: Thienopyrimidines of formula (Ia) or (Ib): wherein R1-R3 have any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase, in particular the p110 delta subtype, such as immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

Abstract: The method of the present invention proposes to induce emotions of happiness or joy in a pregnant mother, with the intended result that the pleasant emotions can then be transmitted to the foetus through the normal mother-foetus communication.

Abstract: A method and system (200) provide automatic and unsupervised morphological analysis of a corpus of a natural language. An optimal division of each word in the corpus is determined (104) and identified stems and suffixes are combined as signatures (106). Major patterns of stem allomorphy are identified (110) and a morphological analysis is produced (112) for subsequent processing.

Abstract: A method of controlling the Sleep pattern of a baby by monitoring its state of sleep to ensure that it enters rapid eye movement sleep to ensure proper development of its central nervous system. If the baby does not enter the rapid eye movement sleep phase, then the baby may be frozen and is reawakened and comforted with smiles and laughter before being returned to sleep.

Abstract: Prosodic databases hold fundamental frequency templates for use in a speech synthesis system. Prosodic database templates may hold fundamental frequency values for syllables in a given sentence. These fundamental frequency values may be applied in synthesizing a sentence of speech. The templates are indexed by tonal pattern markings. A predicted tonal marking pattern is generated for each sentence of text that is to be synthesized, and this predicted pattern of tonal markings is used to locate a best-matching template. The templates are derived by calculating fundamental frequencies on a pursuable basis for sentences that are spoken by a human trainer for a given unlabeled corpus.

Abstract: The present invention provides a method of controlling the sleep pattern of a baby by monitoring its state of sleep to ensure that it enters rapid eye movement sleep to ensure proper development of its central nervous system. If the baby does not enter the rapid eye movement sleep phase, then the baby may be frozen and is reawakened and comforted with smiles and laughter before being returned to sleep.

Abstract: A fluid mixing valve comprising a housing provided with two fluid inlet ports and an outlet port for discharging fluid from the housing, a valve member within a bore in the housing axially movable in the bore for controlling fluid flow from the inlet ports to the outlet port and rotatable in the bore for controlling the relative volume rates of flow through the two inlet ports. The valve member is provided with two arcuate control surfaces eccentric in relation to the axis of rotation of the valve member and each co-operable with separate ones of the ports for inversely controlling, responsive to rotation of the valve member, the relative rates of flow through the individual inlet ports. Preferably one of the control surfaces co-operates with one of the inlet ports and the other co-operates with the outlet port for controlling relative fluid flow through the two inlet ports.